Thoughts on Tmunity’s Decision to Drop TmPSMA-01: Will Companies Opt for More CAR-T Engineering or Better Drugs to Manage MAS?

Tmunity recently disclosed that the FDA enforced the termination of their TmPSMA-01 (PSMA CAR-T) Ph1 trial in prostate cancer following the death of two patients (press release). Below, Celltelligence provides insights on how Tmunity’s PSMA CAR-T compares with key competitors Poseida (P-PSMA-101) and Autolus (AUTO7), while discussing how additional engineering or pharmacological intervention could be needed to improve CAR-T safety in solid tumors.

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.


You’ll be able to access the full article from your Celltelligence Library after signing up.